First Ovarian Cancer Patients Dosed in Phase 2 of OVATION 2 Trial

First Ovarian Cancer Patients Dosed in Phase 2 of OVATION 2 Trial
The first two patients have been randomized in Phase 2 of the OVATION 2 trial testing the immunotherapy candidate GEN-1 in newly diagnosed advanced ovarian cancer. Celsion Corporation, the immunotherapy’s developer, expects to enroll up to 118 patients in this second part of the study by the end of 2021, and will provide clinical updates throughout the course of treatment. “We are delighted to have begun enrolling patients in the Study and look to achieve our goal of providing new novel therapeutic options to patients with this difficult-to-treat cancer,” Michael H. Tardugno, chairman, president, and CEO of Celsion, said in a press release. GEN-1 consists of a DNA vector coding for the pro-inflammatory protein interleukin (IL)-12, one of the most active chemical messengers (cytokines) inducing anti-cancer immunity. However, IL-12 needs to be administered frequently by injection, which may lead to serious toxicity. The investigational treatment was designed to circumvent these issues. It is delivered to the tumor site by nanoparticles designed to carry the DNA vector, th
Subscribe or to access all post and page content.